Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
about
Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functionsThe structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutationsAkt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)mTOR signaling in tumorigenesisOncogenic mutations of PIK3CA in human cancersHS-133, a novel fluorescent phosphatidylinositol 3-kinase inhibitor as a potential imaging and anticancer agent for targeted therapyMuSiC: identifying mutational significance in cancer genomes.Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.EGF-induced activation of Akt results in mTOR-dependent p70S6 kinase phosphorylation and inhibition of HC11 cell lactogenic differentiation.Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment.Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation.A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA geneThe Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.The PIK3CA gene as a mutated target for cancer therapy.Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead.Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers.Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinasePIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunitiest-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer.Up-regulation of PIK3CA promotes metastasis in gastric carcinoma.Structural basis of nSH2 regulation and lipid binding in PI3Kα.KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancerMutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma.Cancer-specific mutations in PIK3CA are oncogenic in vivoActivation of the MEK-S6 pathway in high-grade ovarian cancers.Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression.Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.Role of E542 and E545 missense mutations of PIK3CA in breast cancer: a comparative computational approach.First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancerCurrent status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours.Artemether combined with shRNA interference of vascular cell adhesion molecule-1 significantly inhibited the malignant biological behavior of human glioma cells.Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry.PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
P2860
Q24339544-80DF7794-BB32-4E32-862D-AB4FD343B729Q27649316-2A7878DE-44E5-4E6A-82EB-49E6DCC2ACACQ28080599-BCA82230-6649-4D7E-83C6-92CAE248F7F7Q28252695-4054C49A-0E60-4A77-819F-4BCE40E11130Q28284802-50322482-A618-4F59-B275-B8CE2EB62E1AQ28383826-759A6AF0-4E5B-4783-A88C-B3FF91C9B3D3Q30418806-6DE79443-AA87-4663-BF8B-A2D6C51E5C29Q31096247-AB2B62FC-7BA6-44A9-8CFE-9404705A6ED2Q33258056-2156B3F1-98EF-4C3B-B43F-B16484E3B14FQ33308740-422928EB-08F5-4433-9C65-054A370C7E4CQ33323364-64D0C687-4C08-4A94-B8D3-C474D4B40142Q33403197-54E03DD4-56EC-4A8F-B01A-39D4A997EA87Q33436440-3EFE7650-4E9A-42D2-A679-8448D118EC1BQ33607950-D6660AC6-D071-449B-88AF-E981BFD96392Q33674656-F0766E26-7081-42A6-BA14-076DE40DDE9CQ33699378-EB24B7C7-DB27-4634-AEE8-94F62F56274AQ33716552-A8FDD7FF-6EC8-4CA3-BD53-18A5D3BF9321Q33719411-5A224BA4-7D4A-4E0D-B6F0-CA796696DFF4Q33748323-6D1BEC01-F970-4787-851F-943D28F38ACBQ33889501-D154C70C-36AA-41A5-A81B-97AB30FB6211Q33895741-9EA9036A-5C6C-4263-9BEF-5C04ED0B2DDAQ33933172-85480BEB-750A-41C1-B8F7-93D34AFE3998Q33982322-3406D0EC-2CC9-42F8-834F-A9FD097E9B47Q34139691-B59B98DB-F552-4D31-9733-C57F11A8EA4AQ34156895-F2F50D55-DBBA-450A-98AA-6D3689E8B563Q34213783-C0AB95AC-2112-4F77-9C14-D84C720D6CCEQ34221876-214F1099-CAF6-42E8-9B38-2EDC3FB451A8Q34269163-09B53251-BCD2-4ED9-8610-979ACEC46143Q34330763-65C4BA9E-034B-4066-919B-106D691EFB02Q34335169-9D0DAA26-B2DE-4BDE-98C2-C8EF3F3649E5Q34339010-66B2A654-E9DF-4A14-98EB-A04914AAF0B7Q34402615-78E41297-D579-4B8C-AC46-D1A987B96796Q34486201-AC84DB04-9653-492A-B1EB-307AB064E4F0Q34518245-F33B42EE-0AB1-4619-9DF9-D9919E1C0D5CQ34539092-2C9A797B-D942-4C3F-901F-40782516C3E6Q34626967-DF1B1069-BA2A-4F4C-ABAE-2C39E1345A07Q34634536-C0E9142E-62FF-4A7B-8225-D2E2F69579ACQ34674201-F22F00B9-2F15-4C5F-82B2-A800CC1B0ABCQ34694707-DC37C2DA-89EE-4F2D-8A65-78F4A2B0E4E3Q34769343-AE365866-15F9-4E9C-AF45-0817F36AAC7E
P2860
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
@en
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
@nl
type
label
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
@en
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
@nl
prefLabel
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
@en
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
@nl
P2093
P1476
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
@en
P2093
Cindy J Yee
Douglas A Levine
Faina Bogomolniy
Patrick I Borgen
Richard R Barakat
P304
P356
10.1158/1078-0432.CCR-04-2142
P407
P50
P577
2005-04-01T00:00:00Z